Atlas Trials

BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM

Clinical trial NCT07407010 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07407010
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed Refractory Multiple Myeloma (RRMM)
Start date
2026-06-01
Primary completion
2027-05-31
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.